MMW Fortschr Med. 2000 Mar 13;142 Suppl 1:5-13. Unique Identifier : AIDSLINE MED/20321524
Jablonowski H; Med. Klinik am Stadt. Krankenhaus Salzgitter.
Abstract: For antiretroviral therapy (ART) nucleoside reverse transcriptase inhibitors (NRTI), protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) are available, and are used in combination treatments. The use of PI is associated with new side effects, in particular affecting lipid metabolism. The objective of treatment continues to be a maximum reduction of the viral load. The question whether to treat the HIV early on or later is under controversial discussion. Simplified therapeutic regimens making possible single or twice-daily doses and the use of small numbers of tablets represent a major advance in ART.
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .